Vaccines against human enteric bacterial pathogens

被引：16
作者：
Dougan, G [1 ]
Huett, A [1 ]
Clare, S [1 ]
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, Dept Biol Sci, London SW7 2AZ, England
来源：
BRITISH MEDICAL BULLETIN | 2002年 / 62卷
关键词：
D O I：
10.1093/bmb/62.1.113
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The development of vaccines against enteric bacterial pathogens presents a challenge because of the large number of pathogens capable of causing disease and the requirement to induce immunity that is effective in the gut. A new generation of enteric vaccines based either on live or non-living antigens delivered orally or by injection are reaching the clinic in the early phases of evaluation. However, considerable technical barriers have to be overcome before these vaccines reach the general population.
引用
收藏
页码：113 / 123
页数：11
相关论文
共 44 条
  • [11] SELECTION AND CHARACTERISTICS OF A VIBRIO-CHOLERAE MUTANT LACKING THE A (ADP-RIBOSYLATING) PORTION OF THE CHOLERA ENTEROTOXIN
    HONDA, T
    FINKELSTEIN, RA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (04) : 2052 - 2056
  • [12] Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine
    Jertborn, M
    Åhrén, C
    Svennerholm, AM
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2001, 8 (02) : 424 - 428
  • [13] Kaistha J, 1996, Indian J Pathol Microbiol, V39, P287
  • [14] Induction of mucosal and systemic immune response by oral immunization with H-pylori lysates encapsulated in poly(D,L-lactide-co-glycolide) microparticles
    Kim, SY
    Doh, HJ
    Ahn, JS
    Ha, YJ
    Jang, MH
    Chung, SI
    Park, HJ
    [J]. VACCINE, 1999, 17 (06) : 607 - 616
  • [15] Local and systemic immune responses to combined Vibrio cholerae CVD103-HgR and Salmonella typhi Ty21a live oral vaccines after primary immunization and reimmunization
    Kollaritsch, H
    Cryz, SJ
    Lang, AB
    Herzog, C
    Que, JU
    Wiedermann, G
    [J]. VACCINE, 2000, 18 (26) : 3031 - 3039
  • [16] Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG
    Kotloff, KL
    Noriega, F
    Losonsky, GA
    Sztein, MB
    Wasserman, SS
    Nataro, JP
    Levine, MM
    [J]. INFECTION AND IMMUNITY, 1996, 64 (11) : 4542 - 4548
  • [17] Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans
    Kotloff, KL
    Noriega, FR
    Samandari, T
    Sztein, MB
    Losonsky, GA
    Nataro, JP
    Picking, WD
    Barry, EM
    Levine, MM
    [J]. INFECTION AND IMMUNITY, 2000, 68 (03) : 1034 - 1039
  • [18] Levine M M, 1983, Dev Biol Stand, V53, P59
  • [19] Optimism over vaccines administered via mucosal surfaces
    Levine, MM
    Dougan, G
    [J]. LANCET, 1998, 351 (9113) : 1375 - 1376
  • [20] EVALUATION IN HUMANS OF ATTENUATED VIBRIO-CHOLERAE EL-TOR OGAWA STRAIN TEXAS STAR-SR AS A LIVE ORAL VACCINE
    LEVINE, MM
    BLACK, RE
    CLEMENTS, ML
    LANATA, C
    SEARS, S
    HONDA, T
    YOUNG, CR
    FINKELSTEIN, RA
    [J]. INFECTION AND IMMUNITY, 1984, 43 (02) : 515 - 522
12345